Androgens in Health and Disease.pdf - E Library

Table 3 (continued)
∆LDL ∆HDL ∆other risk
Study (ref.) Patients Mode of treatment Duration cholesterol cholesterol ∆TG factors
Zmuda et al. 1993 (152) 14 Eugonadal men 200 mg TE im/wk, 3 wk +2% –15% +17%
250 mg testolactone/d, –3% –4% –13%
or both –1% –20% +3%
Bagatell et al. 1994 (153) 19 Eugonadal men 200 mg TE im/wk 20 wk –6%* –15%* +5% ApoA-I: –8%
Meriggiola et al. 1995 (154) 36 Eugonadal men 200 mg TE im/wk 1 yr –8% –16% n.d.
Anderson et al., 1995 (155) 63 Eugonadal men 200 mg TE im/wk 1 yr n.s. –13%*** n.s. Lp(a): –25%
Wu et al. 1995 (156) 189 Non-Chinese men 200 mg TE im/wk 1 yr n.s. –14% +10%
82 Chinese men 200 mg TE im/wk 1 yr –2% (all)
Marcovina et al. 1996 (157) 19 Eugonadal men 200 mg TE im/wk 20 wk –8% –14%* +13% Lp(a): –22%**
Grinspoon et al. 2000 (158) 54 Men with AIDS 200 mg TE im/wk 12 wk –6% –8%* –25%
Bhasin et al. 2001 (159) 61 Eugonadal men 25, 50, 125, 300, or 20 wk n.d. Dose- n.d.
with suppressed T 600 mg TE im/wk dependent+
10% to
–20%***
Uyanik et al. 1997 (160) 37 Eugonadal men 120 mg TU po/d 2 mo –25%** +3% –4% APOA-I: –15%
ApoB: +12%
∆LDL, cholesterol change in plasma LDL cholesterol from pretreatment baseline; ∆HDL, cholesterol change in plasma HDL cholesterol from pretreatment baseline;
∆TG, change in plasma triglcerides from pretreatment baseline; T, testosterone; TE, testosterone enanthate; TC, testosterone cypionate; TU, testosterone undecanoate;
TI, testosterone isobutyrate; DHT, dihydrotestosterone; n.s., not significant; n.d.: not done.
Changes were compared to follow-up, baseline (screening) are implausibly extreme and different from follow-up.
*p < 0.05, ** p < 0.01, *** p < 0.001 (as indicated by the authors of the original publications).
202 Wu and von Eckardstein